Individuals with depression, on common, die prematurely, have excessive ranges of bodily comorbidities and might expertise accelerated organic ageing. A larger understanding of age-related changes in physiology might present novel organic insights that will assist inform methods to mitigate extra mortality in depression. We used generalised additive fashions to look at age-related changes in 15 cardiovascular, body composition, grip strength and lung operate measures, evaluating males and females with a lifetime historical past of depression to wholesome controls.
The important dataset included 342,393 adults (imply age = 55.87 years, SD = 8.09; 52.61% females). We discovered statistically important case-control variations for many physiological measures. There was some proof that age-related changes in body composition, cardiovascular operate, lung operate and heel bone mineral density adopted totally different trajectories in depression.
These variations didn’t uniformly slender or widen with age and differed by intercourse. For instance, BMI in feminine instances was 1.1 kg/m2 larger at age 40 and this distinction narrowed to 0.four kg/m2 at age 70. In males, systolic blood strain was 1 mmHg decrease in depression instances at age 45 and this distinction widened to 2.5 mmHg at age 65. These findings counsel that focused screening for physiological operate in middle-aged and older adults with depression is warranted to probably mitigate extra mortality.
Can an information pushed weight problems classification system establish these susceptible to extreme COVID-19 in the UK Biobank cohort research?
COVID-19 is a illness that has been proven to have outcomes that fluctuate by sure socio-demographic and socio-economic teams. It is more and more vital that an understanding of those outcomes ought to be derived not from the consideration of 1 facet, however by a extra multi-faceted understanding of the particular person. In this research use is fabricated from a latest weight problems pushed classification of contributors in the United Kingdom Biobank (UKB) to establish traits in COVID-19 outcomes.
This classification is knowledgeable by a lately created weight problems methods map, and the COVID-19 outcomes are: endeavor a take a look at, a optimistic take a look at, hospitalisation and mortality. It is demonstrated that the classification is ready to establish significant differentials in these outcomes. This extra holistic strategy is advisable for identification and prioritisation of COVID-19 threat and attainable long-COVID willpower.
Whole-exome imputation inside UK Biobank powers uncommon coding variant affiliation and fine-mapping analyses
Exome affiliation research thus far have typically been underpowered to systematically consider the phenotypic affect of very uncommon coding variants. We leveraged in depth haplotype sharing between 49,960 exome-sequenced UK Biobank contributors and the the rest of the cohort (complete n ≈ 500,000) to impute exome-wide variants with accuracy R2 > 0.5 all the way down to minor allele frequency (MAF) ~0.00005.
Association and fine-mapping analyses of 54 quantitative traits recognized 1,189 important associations (P < 5 × 10-8) involving 675 distinct uncommon protein-altering variants (MAF < 0.01) that handed stringent filters for seemingly causality.
Across all traits, 49% of associations (578/1,189) occurred in genes with two or extra hits; follow-up analyses of those genes recognized allelic collection containing as much as 45 distinct ‘likely-causal’ variants. Our outcomes exhibit the utility of within-cohort imputation in population-scale genome-wide affiliation research, present a catalog of likely-causal, large-effect coding variant associations and foreshadow the insights that shall be revealed as genetic biobank research proceed to develop.
The governance of genomic biobank analysis in Africa: reframing the regulatory tilt
Genomic biobank analysis has skilled exponential progress in latest years. It represents an actual alternative to treatment international well being inequity that has seen restricted funding in ailments affecting populations from low- and middle-income international locations. Previous analysis in Africa was restricted to so-called parachute analysis, whereby samples had been taken from native populations to be used in high-income international locations with no native oversight or use of the pattern.
These exploitative practices have to be guarded towards, however the present regulation of genomic analysis in Africa adopts a precautionary strategy that at instances is restrictive in nature. We argue that the regulation and oversight of genomic biobank analysis ought to guard towards exploitative analysis, however in a fashion that promotes reciprocal profit and not restrictive analysis practices. To obtain this, there have to be a rebalancing of the regulatory tilt.
The biobank of barretos most cancers hospital: 14 years of expertise in most cancers analysis
Despite the developments in most cancers analysis over years, most cancers remains to be considered one of the main causes of loss of life worldwide. In Brazil, the variety of most cancers instances for the a number of subsequent years (2020-2022) is predicted to extend as much as 625,000. Thus, translational analysis has been important to find out the potential threat, prognostic, and predictive biomarkers in most cancers. Therefore, Barretos Cancer Hospital applied a biobank (BB-BCH) in 2006, which is liable for processing, storage, and provision of organic supplies from most cancers and non-cancer contributors.
Hence, this text aimed to explain BB-BCH’s historical past, experiences, and outcomes and discover its affect on Brazilian translational oncology analysis state of affairs. BB-BCH has a multidisciplinary group who’re liable for guaranteeing the high quality of all processes as advisable by worldwide pointers for biobanks. Furthermore, BB-BCH has ample gear to make sure the high quality of all materials requested by researchers as genetic materials (DNA and RNA) and/or total biospecimens.
Goniometer base type B1, MicroRT compatible |
|||
| GB-B1-40 | MiTeGen | 40 BASES | 226 EUR |
|
Description: Goniometer base type B1, MicroRT compatible; package of 40 |
|||
Goniometer base type B1, MicroRT compatible |
|||
| GB-B1-500 | MiTeGen | 500 BASES | 2418 EUR |
|
Description: Goniometer base type B1, MicroRT compatible; package of 500 |
|||
Transforming Growth Factor Beta 1 (TGF-B1) Antibody |
|||
| abx122703-100ug | Abbexa | 100 ug | 469.2 EUR |
Goniometer base type B1-R, MicroRT compatible |
|||
| GB-B1-R-10 | MiTeGen | 10 BASES | 118 EUR |
|
Description: Goniometer base type B1-R, MicroRT compatible; package of 10 |
|||
Goniometer base type B1-R, MicroRT compatible |
|||
| GB-B1-R-100 | MiTeGen | 100 BASES | 939 EUR |
|
Description: Goniometer base type B1-R, MicroRT compatible; package of 100 |
|||
Goniometer base type B1-R, MicroRT compatible |
|||
| GB-B1-R-1000 | MiTeGen | 1000 BASES | 8773 EUR |
|
Description: Goniometer base type B1-R, MicroRT compatible; package of 1000 |
|||
Goniometer base type B1-R, MicroRT compatible |
|||
| GB-B1-R-20 | MiTeGen | 20 BASES | 211 EUR |
|
Description: Goniometer base type B1-R, MicroRT compatible; package of 20 |
|||
Goniometer base type B1-R, MicroRT compatible |
|||
| GB-B1-R-40 | MiTeGen | 40 BASES | 400 EUR |
|
Description: Goniometer base type B1-R, MicroRT compatible; package of 40 |
|||
Goniometer base type B1-R, MicroRT compatible |
|||
| GB-B1-R-500 | MiTeGen | 500 BASES | 4442 EUR |
|
Description: Goniometer base type B1-R, MicroRT compatible; package of 500 |
|||
Mouse Transforming Growth Factor beta1 (TGF-b1) CLIA Kit |
|||
| abx196294-96tests | Abbexa | 96 tests | 990 EUR |
Rat Transforming Growth Factor beta1 (TGF-b1) CLIA Kit |
|||
| abx196295-96tests | Abbexa | 96 tests | 990 EUR |
Human Transforming Growth Factor Beta 1 (TGF-b1) CLIA Kit |
|||
| abx196293-96tests | Abbexa | 96 tests | 990 EUR |
Human Transforming growth factor beta 1 (TGF-b1) ELISA Kit |
|||
| LF-EK60028 | Abfrontier | 1×96T | 948 EUR |
TGF |
|||
| ABD8749 | Lifescience Market | 100 ug | 525.6 EUR |
TGF |
|||
| ABF5347 | Lifescience Market | 100 ug | 525.6 EUR |
TGF |
|||
| ABF8080 | Lifescience Market | 100 ug | 525.6 EUR |
TGF |
|||
| ABF8081 | Lifescience Market | 100 ug | 525.6 EUR |
TGF- |
|||
| EF016694 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF |
|||
| EF016747 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF016878 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF017053 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF017054 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF017076 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF018074 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF019518 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF012749 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF012916 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF012917 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF012918 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF |
|||
| EF000223 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF |
|||
| EF000225 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF |
|||
| EF000226 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF |
|||
| EF000227 | Lifescience Market | 96 Tests | 826.8 EUR |
TGF- |
|||
| EF010976 | Lifescience Market | 96 Tests | 826.8 EUR |
Protein B1 (B1) Antibody |
|||
| 20-abx317795 | Abbexa |
|
|
TGF beta |
|||
| MO20012 | Neuromics | 100 ul. | 295.2 EUR |
TGF-beta3 |
|||
| GT15074 | Neuromics | 100 ug | 631.2 EUR |
TGF Beta1 |
|||
| PR15009 | Neuromics | 1 ug | 451.2 EUR |
TGF Beta1 |
|||
| PR27106 | Neuromics | 2 ug | 308.4 EUR |
TGF Beta3 |
|||
| PR27164 | Neuromics | 2 ug | 229.2 EUR |
TGF Beta2 |
|||
| PR27165 | Neuromics | 5 ug | 381.6 EUR |
TGF-Beta/ Rat TGF- Beta ELISA Kit |
|||
| ELA-E1949r | Lifescience Market | 96 Tests | 1063.2 EUR |
TGF-Alpha/ Rat TGF- Alpha ELISA Kit |
|||
| ELA-E0123r | Lifescience Market | 96 Tests | 1063.2 EUR |
TGF-Beta1/ Rat TGF- Beta1 ELISA Kit |
|||
| ELA-E0124r | Lifescience Market | 96 Tests | 1063.2 EUR |
Ephrin B1 (Ephrin B1) Antibody |
|||
| abx232810-100ug | Abbexa | 100 ug | 577.2 EUR |
Protein B1 (B1) Antibody (HRP) |
|||
| 20-abx317796 | Abbexa |
|
|
Protein B1 (B1) Antibody (FITC) |
|||
| 20-abx317797 | Abbexa |
|
|
Protein B1 (B1) Antibody (Biotin) |
|||
| 20-abx317798 | Abbexa |
|
|
TGF alpha Antibody |
|||
| DF6099 | Affbiotech | 200ul | 420 EUR |
TGF beta2 Antibody |
|||
| AF0260 | Affbiotech | 200ul | 420 EUR |
TGF alpha Antibody |
|||
| AF0262 | Affbiotech | 200ul | 420 EUR |
TGF beta1 Antibody |
|||
| AF1027 | Affbiotech | 200ul | 420 EUR |
TGF? Polyclonal Antibody |
|||
| ES3593-100ul | ELK Biotech | 100ul | 334.8 EUR |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat/Monkey. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
TGF? Polyclonal Antibody |
|||
| ES3593-50ul | ELK Biotech | 50ul | 248.4 EUR |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat/Monkey. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
TGF? Polyclonal Antibody |
|||
| ES8382-100ul | ELK Biotech | 100ul | 334.8 EUR |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
TGF? Polyclonal Antibody |
|||
| ES8382-50ul | ELK Biotech | 50ul | 248.4 EUR |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
TGF alpha antibody |
|||
| 70R-50472 | Fitzgerald | 100 ul | 292.8 EUR |
|
Description: Purified Polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-51342 | Fitzgerald | 100 ul | 292.8 EUR |
|
Description: Purified Polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-30774 | Fitzgerald | 100 ug | 392.4 EUR |
|
Description: Rabbit polyclonal TGF alpha antibody |
|||
TGF alpha Antibody |
|||
| 49822-100ul | SAB | 100ul | 399.6 EUR |
TGF alpha Antibody |
|||
| 49822-50ul | SAB | 50ul | 286.8 EUR |
Pro-TGF-a |
|||
| 5-01812 | CHI Scientific | 4 x 5mg | Ask for price |
TGF-alpha Antibody |
|||
| 5339-100 | Biovision | 379.2 EUR | |
TGF-alpha Antibody |
|||
| 5339-30T | Biovision | 175.2 EUR | |
TGF-beta2 Antibody |
|||
| 5340-100 | Biovision | 379.2 EUR | |
TGF-beta2 Antibody |
|||
| 5340-30T | Biovision | 175.2 EUR | |
TGF-beta2 Antibody |
|||
| 5343R-100 | Biovision | 379.2 EUR | |
TGF-beta2 Antibody |
|||
| 5343R-30T | Biovision | 175.2 EUR | |
TGF-beta3 Antibody |
|||
| 5344R-100 | Biovision | 379.2 EUR | |
TGF-beta3 Antibody |
|||
| 5344R-30T | Biovision | 175.2 EUR | |
TGF-?1 Antibody |
|||
| 5559-100 | Biovision | 483.6 EUR | |
TGF-?1 Antibody |
|||
| 5559-30T | Biovision | 196.8 EUR | |
TGF alpha antibody |
|||
| 70R-12318 | Fitzgerald | 100 ug | 483.6 EUR |
|
Description: Rabbit polyclonal TGF alpha antibody |
|||
TGF beta antibody |
|||
| 70R-12368 | Fitzgerald | 100 ug | 632.4 EUR |
|
Description: Rabbit polyclonal TGF beta antibody |
|||
TGF alpha antibody |
|||
| 70R-15427 | Fitzgerald | 100 ug | 392.4 EUR |
|
Description: Rabbit polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70-TG89 | Fitzgerald | 1 mg | 974.4 EUR |
|
Description: Affinity purified Goat polyclonal TGF alpha antibody |
|||
TGF beta antibody |
|||
| 70-TG90 | Fitzgerald | 1 mg | 946.8 EUR |
|
Description: Affinity purified Goat polyclonal TGF beta antibody |
|||
TGF alpha antibody |
|||
| 70-TR56 | Fitzgerald | 50 ug | 357.6 EUR |
|
Description: Affinity purified Rabbit polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-13903 | Fitzgerald | 100 ug | 386.4 EUR |
|
Description: Affinity purified Sheep polyclonal TGF alpha antibody |
|||
TGF alpha protein |
|||
| 30R-2357 | Fitzgerald | 20 ug | 268.8 EUR |
|
Description: Purified recombinant Human TGF alpha protein |
|||
TGF-b Antibody |
|||
| 21678-100ul | SAB | 100ul | 302.4 EUR |
TGF-b Antibody |
|||
| 21678-50ul | SAB | 50ul | 224.4 EUR |
TGF β2 Antibody |
|||
| 33497-100ul | SAB | 100ul | 302.4 EUR |
TGF β2 Antibody |
|||
| 33497-50ul | SAB | 50ul | 224.4 EUR |
TGF β3 Antibody |
|||
| 33498-100ul | SAB | 100ul | 302.4 EUR |
TGF β3 Antibody |
|||
| 33498-50ul | SAB | 50ul | 224.4 EUR |
TGF alpha Antibody |
|||
| 33499-100ul | SAB | 100ul | 302.4 EUR |
TGF alpha Antibody |
|||
| 33499-50ul | SAB | 50ul | 224.4 EUR |
TGF alpha antibody |
|||
| 20C-CR2026SP | Fitzgerald | 2.5 mg | 448.8 EUR |
|
Description: Sheep polyclonal TGF alpha antibody |
|||
TGF beta antibody |
|||
| 10R-6686 | Fitzgerald | 50 ug | 217.2 EUR |
|
Description: Rat monoclonal TGF beta antibody |
|||
TGF beta antibody |
|||
| 10R-7765 | Fitzgerald | 500 ug | 678 EUR |
|
Description: Mouse monoclonal TGF beta antibody |
|||
TGF alpha protein |
|||
| 30R-AT002 | Fitzgerald | 20 ug | 159.6 EUR |
|
Description: Purified recombinant Human TGF alpha protein |
|||
TGF alpha antibody |
|||
| 10R-T120a | Fitzgerald | 100 ug | 600 EUR |
|
Description: Mouse monoclonal TGF alpha antibody |
|||
TGF beta2 Antibody |
|||
| ABF0260 | Lifescience Market | 100 ug | 525.6 EUR |
TGF alpha Antibody |
|||
| ABF0262 | Lifescience Market | 100 ug | 525.6 EUR |
TGF beta1 Antibody |
|||
| ABF1027 | Lifescience Market | 100 ug | 525.6 EUR |
TGF beta1 Antibody |
|||
| BF0173 | Affbiotech | 200ul | 540 EUR |
TGF beta1 Antibody |
|||
| BF0334 | Affbiotech | 200ul | 540 EUR |
Human TGF-β3 |
|||
| BJU020 | GroPep | 20 µg | 303.6 EUR |
Human TGF-β3 |
|||
| BJU100 | GroPep | 100 µg | 415.2 EUR |
TGF-beta1, Human |
|||
| HY-P7118 | MedChemExpress | 100ug | 1465.2 EUR |
TGF-beta2, Human |
|||
| HY-P7119 | MedChemExpress | 50ug | 1148.4 EUR |
TGF-α, Human |
|||
| HY-P7411 | MedChemExpress | 50ug | 280.8 EUR |
TGF-alpha, CF |
|||
| PR15016CF | Neuromics | 500 ug | 1610.4 EUR |
Goat(TGF-β) |
|||
| QY-E140043 | Qayee Biotechnology | 96T | 495.6 EUR |
pET-28a-TGF |
|||
| PVTB00118-1a | Lifescience Market | 2 ug | 427.2 EUR |
anti-TGF alpha |
|||
| YF-PA24840 | Abfrontier | 50 ul | 400.8 EUR |
|
Description: Mouse polyclonal to TGF alpha |
|||
anti-TGF alpha |
|||
| YF-PA15003 | Abfrontier | 100 ug | 483.6 EUR |
|
Description: Rabbit polyclonal to TGF alpha |
|||
TGF alpha Antibody |
|||
| R30427 | NSJ Bioreagents | 100 ug | 419 EUR |
TGF alpha Antibody |
|||
| RQ4870 | NSJ Bioreagents | 100ul | 419 EUR |
TGF alpha Antibody |
|||
| V2266-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: TGF alpha is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. Staining with the antibody is completely blocked by the peptide used for raising this antibody. |
|||
TGF alpha Antibody |
|||
| V2266-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: TGF alpha is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. Staining with the antibody is completely blocked by the peptide used for raising this antibody. |
|||
TGF alpha Antibody |
|||
| V2266SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: TGF alpha is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. Staining with the antibody is completely blocked by the peptide used for raising this antibody. |
|||
TGF alpha Antibody |
|||
| V2267-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: TGF alpha is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. Staining with the antibody is completely blocked by the peptide used for raising this antibody. |
|||
TGF alpha Antibody |
|||
| V2267-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: TGF alpha is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. Staining with the antibody is completely blocked by the peptide used for raising this antibody. |
|||
TGF alpha Antibody |
|||
| V2267SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: TGF alpha is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. Staining with the antibody is completely blocked by the peptide used for raising this antibody. |
|||
TGF alpha Antibody |
|||
| V2885-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. The staining with this mAb is completely blocked by the peptide used for raising this antibody. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V2885-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: This antibody reacts with the TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. The staining with this mAb is completely blocked by the peptide used for raising this antibody. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V2885SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. The staining with this mAb is completely blocked by the peptide used for raising this antibody. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V2886-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. The staining with this mAb is completely blocked by the peptide used for raising this antibody. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V2886-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: This antibody reacts with the TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. The staining with this mAb is completely blocked by the peptide used for raising this antibody. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V2886SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. The staining with this mAb is completely blocked by the peptide used for raising this antibody. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V2888-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V2888-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V2888IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
|
Description: This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V2888SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V7158-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: Transforming growth factor alpha is a protein that in humans is encoded by the TGFA gene. As a member of the epidermal growth factor (EGF) family, TGFa is a mitogenic polypeptide. The protein becomes activated when binding to receptors capable of protein kinase activity for cellular signaling. TGFa is a transforming growth factor that is a ligand for the epidermal growth factor receptor, which activates a signaling pathway for cell proliferation, differentiation and development. This protein may act as either a transmembrane-bound ligand or a soluble ligand. This gene has been associated with many types of cancers, and it may also be involved in some cases of cleft lip/palate. [Wiki] |
|||
TGF alpha Antibody |
|||
| V7158-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: Transforming growth factor alpha is a protein that in humans is encoded by the TGFA gene. As a member of the epidermal growth factor (EGF) family, TGFa is a mitogenic polypeptide. The protein becomes activated when binding to receptors capable of protein kinase activity for cellular signaling. TGFa is a transforming growth factor that is a ligand for the epidermal growth factor receptor, which activates a signaling pathway for cell proliferation, differentiation and development. This protein may act as either a transmembrane-bound ligand or a soluble ligand. This gene has been associated with many types of cancers, and it may also be involved in some cases of cleft lip/palate. [Wiki] |
|||
TGF alpha Antibody |
|||
| V7158IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
|
Description: Transforming growth factor alpha is a protein that in humans is encoded by the TGFA gene. As a member of the epidermal growth factor (EGF) family, TGFa is a mitogenic polypeptide. The protein becomes activated when binding to receptors capable of protein kinase activity for cellular signaling. TGFa is a transforming growth factor that is a ligand for the epidermal growth factor receptor, which activates a signaling pathway for cell proliferation, differentiation and development. This protein may act as either a transmembrane-bound ligand or a soluble ligand. This gene has been associated with many types of cancers, and it may also be involved in some cases of cleft lip/palate. [Wiki] |
|||
TGF alpha Antibody |
|||
| V7158SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: Transforming growth factor alpha is a protein that in humans is encoded by the TGFA gene. As a member of the epidermal growth factor (EGF) family, TGFa is a mitogenic polypeptide. The protein becomes activated when binding to receptors capable of protein kinase activity for cellular signaling. TGFa is a transforming growth factor that is a ligand for the epidermal growth factor receptor, which activates a signaling pathway for cell proliferation, differentiation and development. This protein may act as either a transmembrane-bound ligand or a soluble ligand. This gene has been associated with many types of cancers, and it may also be involved in some cases of cleft lip/palate. [Wiki] |
|||
TGF alpha Antibody |
|||
| V9085-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGF-a is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V9085-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGF-a is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V9085SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the C-terminus of TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGF-a is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V9086-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V9086-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: This antibody reacts with the TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
TGF alpha Antibody |
|||
| V9086SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: This antibody reacts with the TGF alpha and shows no cross-reaction with EGF and the neuropeptide synenkephalin. TGFa is a growth factor with 33% homology to EGF, binds to EGFR, activates tyrosine phosphorylation of the receptor, and stimulates cell proliferation. It plays a role in tumor initiation by inducing the reversible transformed phenotype. |
|||
MicroMesh Epoxied Assembly Head Diameter and Mesh Opening 300/25IN1 (in um) Base Style B1 |
|||
| B-M3-300/25IN1-B1 | MiTeGen | 20 MOUNT/BASE ASSEMBLIES | 249 EUR |
|
Description: MicroMesh Epoxied Assembly Head Diameter and Mesh Opening 300/25IN1 (in um) Base Style B1 |
|||
MicroMesh Epoxied Assembly Head Diameter and Mesh Opening 400/25IN1 (in um) Base Style B1 |
|||
| B-M3-400/25IN1-B1 | MiTeGen | 20 MOUNT/BASE ASSEMBLIES | 249 EUR |
|
Description: MicroMesh Epoxied Assembly Head Diameter and Mesh Opening 400/25IN1 (in um) Base Style B1 |
|||
MicroMesh Epoxied Assembly Head Diameter and Mesh Opening 400/25IN2 (in um) Base Style B1 |
|||
| B-M3-400/25IN2-B1 | MiTeGen | 20 MOUNT/BASE ASSEMBLIES | 249 EUR |
|
Description: MicroMesh Epoxied Assembly Head Diameter and Mesh Opening 400/25IN2 (in um) Base Style B1 |
|||
Coxsackievirus (B1) |
|||
| DAG4690 | Creative Diagnostics | 0.25 mg | Ask for price |
Enniatin B1 |
|||
| E038-1MG | TOKU-E | 1 mg | 268.8 EUR |
Enniatin B1 |
|||
| E038-5MG | TOKU-E | 5 mg | 849.6 EUR |
Polymyxin B1 |
|||
| C3598-1 | ApexBio | 1 mg | 223.2 EUR |
|
Description: Polymyxin B1 can bind and kill Gram-negative bacteria.In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. |
|||
Polymyxin B1 |
|||
| C3598-10 | ApexBio | 10 mg | 1104 EUR |
|
Description: Polymyxin B1 can bind and kill Gram-negative bacteria.In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. |
|||
Polymyxin B1 |
|||
| C3598-5 | ApexBio | 5 mg | 714 EUR |
|
Description: Polymyxin B1 can bind and kill Gram-negative bacteria.In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. |
|||
B1 Antibody |
|||
| 1-CSB-PA882501LA01HKA | Cusabio |
|
|
|
Description: A polyclonal antibody against B1. Recognizes B1 from Human herpesvirus 6B. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
|||
Fumonisin B1 |
|||
| F030-0.5MG | TOKU-E | 0.5 mg | 184.8 EUR |
Fumonisin B1 |
|||
| F030-2.5MG | TOKU-E | 2.5 mg | 558 EUR |
Aflatoxin B1 |
|||
| A115-1MG | TOKU-E | 1 mg | 142.8 EUR |
Aflatoxin B1 |
|||
| A115-5MG | TOKU-E | 5 mg | 410.4 EUR |
Avermectin B1 |
|||
| A3202-100 | ApexBio | 100 mg | 134.4 EUR |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Avermectin B1 |
|||
| A3202-1000 | ApexBio | 1 g | 172.8 EUR |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Avermectin B1 |
|||
| A3202-10000 | ApexBio | 10 g | 811.2 EUR |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Avermectin B1 |
|||
| A3202-5000 | ApexBio | 5 g | 474 EUR |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Fumonisin B1 |
|||
| 20-abx076560 | Abbexa |
|
|
Fumonisin B1 |
|||
| A4537-1 | ApexBio | 1 mg | 158.4 EUR |
|
Description: Mycotoxin produced by Fusarium moniliforme. Potently inhibits sphingosine N-acyltransferase (ceramide synthase), causing an accumulation of sphingoid bases (IC50 ~ 75 nM). |
|||
Fumonisin B1 |
|||
| A4537-10 | ApexBio | 10 mg | 799.2 EUR |
|
Description: Mycotoxin produced by Fusarium moniliforme. Potently inhibits sphingosine N-acyltransferase (ceramide synthase), causing an accumulation of sphingoid bases (IC50 ~ 75 nM). |
|||
Fumonisin B1 |
|||
| A4537-5 | ApexBio | 5 mg | 502.8 EUR |
|
Description: Mycotoxin produced by Fusarium moniliforme. Potently inhibits sphingosine N-acyltransferase (ceramide synthase), causing an accumulation of sphingoid bases (IC50 ~ 75 nM). |
|||
Bafilomycin B1 |
|||
| B039-1MG | TOKU-E | 1 mg | 188.4 EUR |
Bafilomycin B1 |
|||
| B039-5MG | TOKU-E | 5 mg | 567.6 EUR |
Demethylasterriquinone B1 |
|||
| B6869-1 | ApexBio | 1 mg | 151.2 EUR |
Demethylasterriquinone B1 |
|||
| B6869-5 | ApexBio | 5 mg | 417.6 EUR |
Proanthocyanidin B1 |
|||
| N2180-5 | ApexBio | 5 mg | 686.4 EUR |
|
Description: Extracted from Betula pubescens Ehrh. hypophloedes;Store the product in sealed, cool and dry condition |
|||
Saquayamycin B1 |
|||
| GL5222-1MG | Glentham Life Sciences | 1 mg | 274.8 EUR |
Saquayamycin B1 |
|||
| GL5222-500UG | Glentham Life Sciences | 500 ug | 206.4 EUR |
Saquayamycin B1 |
|||
| GL5222-5MG | Glentham Life Sciences | 5 mg | 661.2 EUR |
From 2006 to 2019, BB-BCH contained 252,069 samples from 44,933 contributors, the entire assortment is represented by 15 various kinds of biospecimens collected from them. According to our information, the most collected and saved topography in males is head and neck (29%); in girls is breast (28%); and in youngsters is torso and limb (27%) samples. Finally, we supported nationwide and worldwide consortia and initiatives equivalent to The Cancer Genome Atlas. BB-BCH is a crucial data supply for scientific group, enabling the growth of high-quality research, with all kinds of tumor classes and excessive nationwide representativeness of Brazilian inhabitants.